Literature DB >> 9133546

Glucagon-like peptide I and glucose-dependent insulinotropic polypeptide stimulate Ca2+-induced secretion in rat alpha-cells by a protein kinase A-mediated mechanism.

W G Ding1, E Renström, P Rorsman, K Buschard, J Gromada.   

Abstract

High-resolution capacitance measurements were used to explore the effects of the gut hormones GLP-I(7-36) amide [glucagon-like peptide I(7-36) amide] and GIP (glucose-dependent insulinotropic polypeptide) on Ca2+-dependent exocytosis in glucagon-secreting rat pancreatic alpha-cells. Both peptides produced a greater than threefold potentiation of secretion evoked by voltage-clamp depolarizations, an effect that was associated with an approximately 35% increase of the Ca2+ current. The stimulatory actions of GLP-I(7-36) amide and GIP were mimicked by forskolin and antagonized by the protein kinase A (PKA)-inhibitor Rp-8-Br-cAMPS. The islet hormone somatostatin inhibited the stimulatory action of GLP-I(7-36) amide and GIP via a cyclic AMP-independent mechanism, whereas insulin had no effect on exocytosis. These data suggest that the alpha-cells are equipped with receptors for GLP-I and GIP and that these peptides, in addition to their well-established insulinotropic capacity, also stimulate glucagon secretion. We propose that the reported inhibitory action of GLP-I on glucagon secretion is accounted for by a paracrine mechanism (e.g., mediated by stimulated release of somatostatin that in turn suppresses exocytosis in the alpha-cell).

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9133546     DOI: 10.2337/diab.46.5.792

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  27 in total

1.  Somatostatin inhibits exocytosis in rat pancreatic alpha-cells by G(i2)-dependent activation of calcineurin and depriming of secretory granules.

Authors:  J Gromada; M Høy; K Buschard; A Salehi; P Rorsman
Journal:  J Physiol       Date:  2001-09-01       Impact factor: 5.182

Review 2.  Glucagon-like peptide 1 (GLP-1).

Authors:  T D Müller; B Finan; S R Bloom; D D'Alessio; D J Drucker; P R Flatt; A Fritsche; F Gribble; H J Grill; J F Habener; J J Holst; W Langhans; J J Meier; M A Nauck; D Perez-Tilve; A Pocai; F Reimann; D A Sandoval; T W Schwartz; R J Seeley; K Stemmer; M Tang-Christensen; S C Woods; R D DiMarchi; M H Tschöp
Journal:  Mol Metab       Date:  2019-09-30       Impact factor: 7.422

3.  Pancreatic safety of GLP-1-based therapeutic agents: further insights from rodent studies?

Authors:  Jens Juul Holst
Journal:  Diabetologia       Date:  2013-07-03       Impact factor: 10.122

4.  Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans.

Authors:  J Schirra; K Sturm; P Leicht; R Arnold; B Göke; M Katschinski
Journal:  J Clin Invest       Date:  1998-04-01       Impact factor: 14.808

Review 5.  Regulation of islet glucagon secretion: Beyond calcium.

Authors:  Jing W Hughes; Alessandro Ustione; Zeno Lavagnino; David W Piston
Journal:  Diabetes Obes Metab       Date:  2018-09       Impact factor: 6.577

Review 6.  GLP-1R and amylin agonism in metabolic disease: complementary mechanisms and future opportunities.

Authors:  Jonathan D Roth; Mary R Erickson; Steve Chen; David G Parkes
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

7.  R-spondin-1 is a novel beta-cell growth factor and insulin secretagogue.

Authors:  Victor S C Wong; Andrea Yeung; William Schultz; Patricia L Brubaker
Journal:  J Biol Chem       Date:  2010-05-04       Impact factor: 5.157

Review 8.  Glucagon and type 2 diabetes: the return of the alpha cell.

Authors:  Asger Lund; Jonatan I Bagger; Mikkel Christensen; Filip K Knop; Tina Vilsbøll
Journal:  Curr Diab Rep       Date:  2014-12       Impact factor: 4.810

Review 9.  Alpha cell function in health and disease: influence of glucagon-like peptide-1.

Authors:  B E Dunning; J E Foley; B Ahrén
Journal:  Diabetologia       Date:  2005-08-13       Impact factor: 10.122

10.  Effects of short-term intensive glycemic control on insulin, glucagon, and glucagon-like peptide-1 secretion in patients with Type 2 diabetes.

Authors:  M Shimodaira; Y Muroya; N Kumagai; K Tsuzawa; K Honda
Journal:  J Endocrinol Invest       Date:  2013-04-12       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.